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South Africa is currently in the midst of the world’s worst
HIV/AIDS epidemic, carrying 10% of the burden of the disease
while having only 1% of the world’s population. KwaZulu-
Natal, the most populous province, is currently the worst
affected region, with the largest number of infected people in
South Africa.1 The burden of HIV/AIDS has placed a severe
strain on the health services, with estimates of 50% of hospital
beds being occupied by AIDS patients.2 A seroprevalence of
16%3 among health care workers, coupled with a severe
shortage of nurses in South Africa (31 000 nursing posts vacant,
6 098 in KwaZulu-Natal) (Report by Minister of Health,
Parliamentary Question Time, August 2003), suggests a
potentially disastrous impact on provision of health care in the
foreseeable future.
McCord Hospital is a 180-bed, community-orientated
hospital with a staff of 500. It offers a comprehensive package
of prevention, treatment and care for patients with HIV/AIDS.
However, for many staff, providing nursing care to dying
young adults while knowing themselves to be at risk of HIV or
HIV-positive has been a tremendous emotional burden. Despite
the availability of  counselling and support services offered to
patients and the known benefits of antiretroviral (ARV)
therapy,4,5 few staff had been willing to be tested or to come
forward for treatment even when sick. Denial, fear and
hopelessness were common and the lack of easy access to
ARVs for their patients and themselves compounded these
feelings.6
From June to September 2001, 4 female staff members died
of AIDS in the hospital. All these women were afraid of being
tested or identified as being HIV-positive. One knew of her
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positive HIV status but did not inform any of the hospital
doctors looking after her. The other 3 were aware that they
were ill but were not willing to be tested for HIV until very late
in their illness. Their deaths in the hospital wards, being
nursed by their colleagues, with much speculation about the
cause of their illnesses, had a tremendously negative impact on
the morale of the staff. The provision of HAART to HIV-
infected health care workers in South Africa may be critical to
addressing these problems and to maintaining a healthy and
committed workforce able to provide hope and care to HIV-
infected patients.
Setting up the programme
In response to this need, an ARV discussion group was set up
in September 2001 to explore the possibility of accessing ARV
drugs for staff members. An estimate was made of the sick
leave and medical costs of looking after the 4 staff members
who had died during 2001 (Table I).
Given the McCord staff complement of 500 and an assumed
prevalence of 20% it was likely that 100 staff were living with
HIV disease. We estimated that 20% or 25 of these staff
members may need ARV treatment based on the Southern
African HIV Clinicians Society Guidelines.7 At a cost of
approximately R12 000 a year in 2001, the maximum annual
cost was estimated at R300 000. This cost was weighed against
the anticipated increasing health and psychological costs of
HIV disease among hospital staff.
A comprehensive staff HIV management programme
covering testing, prophylaxis, monitoring and triple therapy
with ARVs was developed by the staff doctor (KU) in
consultation with an invited expert in HIV treatment in the
developed world (GF). The programme was then discussed
with various staff and management groups for their input and
was enthusiastically accepted by all, although several concerns
were raised.
Potential problems identified
Three main potential problems were identified during the
process of informing the staff. These were: (i) confidentiality for
the staff; (ii) criteria for staff eligibility and access to therapy;
and (iii) support for adherence to therapy.
Confidentiality
One of the factors contributing to the reluctance of staff to be
tested and treated was the location of HIV services in the HIV
clinic. It was therefore decided to locate the staff HIV services
at the staff clinic. The staff clinic functions as a family practice
for the staff with free consultation, treatment and admission.
This service has been widely used by the staff for some years,
as they do not have medical aid. Staff with tuberculosis (TB)
were already being treated through the staff clinic. The staff
clinic was therefore chosen as the best place to provide a
confidential and comprehensive service.
Confidentiality of blood testing was thought to be critical to
take-up of the service. The staff doctor would do counselling
and blood taking, all HIV bloods from staff would be coded,
and results and consents would be kept in a separate
confidential file. Medical notes on ARV therapy would be kept
discreetly in a separate compartment in the staff member’s
medical file.
Despite a request that ARVs be dispensed by the staff doctor
it was decided that they be dispensed by senior pharmacists.
The hospital staff and counsellors accepted this partly because
the senior dispensary staff were seen as less likely to be on the
gossip network than the dispensary assistants, who were more
likely to be from the same community as the staff requiring
ARV therapy.
Access to therapy
During feedback from the staff there was concern about who
would be eligible for treatment. The decision was made to offer
free treatment to all permanent staff and to all pupil nurses
employed  by McCord Hospital. There was also discussion on
continuing treatment for staff who left the hospital. This was
particularly important in the case of pupil nurses who only
trained at the hospital for 2 years. Staff who left the hospital
would be charged normal outpatient rates but could continue
to be seen by the staff doctor if they wished. The only
exceptions were staff who retired or who were boarded after
more than 10 years of service; they would be given free ARV
therapy if necessary.
For staff members leaving the hospital, but not able to take
over paying for ARVs themselves, all three drugs would be
stopped at one time. Even if they only had a  short period of
ARV therapy they would benefit from the immune
reconstitution, be unlikely to develop resistance and could
recommence the same drugs at any time in the future.
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Table I. Costs of inpatient care and sick leave for 4 staff members
who died of AIDS in 2001
Costs (R)
Employee 1: meningitis 13 000
Employee 2: HIV renal failure 26 800
Employee 3: Kaposi’s sarcoma 42 000
Employee 4: HIV polyneuropathy 24 150
Total costs 105 950
Mean cost per patient 26 500
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Treatment adherence
Recognising the importance of excellent adherence,8-10 various
options to encourage adherence with ARV therapy were
explored. One possibility was supervised treatment akin to the
TB DOTS (directly observed short-course therapy) system.11 We
discussed designating treatment supporters from among the
staff HIV counsellors, but there was concern that  many staff
would not be comfortable with being allocated one of their
colleagues as an HIV treatment supporter. Two strategies were
chosen to try and support adherence with ARV therapy.
The first was thorough information and counselling on ARV
therapy by the staff doctor over two or three visits, discussing
treatment, side-effects, the critical importance of adherence and
the risk of resistance.12 Secondly, staff commencing ARV
therapy would be supplied with seven plastic screw-cap bottles
labelled Monday to Sunday in which they would pack all their
medication for a week including ARV therapy, TB treatment
and prophylactic treatment.
Components of the McCord Hospital
HIV management programme
The HIV management programme includes confidential
counselling and testing by the staff doctor; annual disease stage
assessment and screening including CD4 counts, chest X-rays
and Pap smears; and prophylaxis against TB, pneumocystic
pneumonia and cryptococcal infection. In line with current
World Health Organisation (WHO) recommendations5 and
considering that the hospital could only afford drugs from a
restricted list, therapy is offered to patients with CD4 counts
less than 200 or a CD4 count less than 350 plus significant
symptoms, e.g. atypical TB or prolonged diarrhoea. Monitoring
of therapy is done according to standard recommendations
from the Southern African HIV Clinicians Society Guidelines.7
Drug regimens and costs
The ‘first-step’ ARV therapy was chosen as stavudine (d4T)
and didanosine (ddI) together with either efavirenz or
nevirapine because this was the most cost-effective regimen
available to the hospital at the time (November 2001).
‘Alternative first step’, where ddI would be replaced by
lamivudine (3TC), would be used if there was a strong history
of alcohol abuse or pancreatitis or raised amylase. In the case of
pregnancy, treatment failure or known resistance to the ‘first-
step’ drugs, the ‘second step’ would be zidovudine (AZT), 3TC
and either efavirenz, nevirapine or indinavir. The hospital
would pay for the whole cost of baseline and monitoring tests
and drugs from the ‘first step’ and ‘alternative first step’. The
hospital would subsidise 50% of the cost of drugs from the
‘second step’ (Table II). The cost of other ARVs precluded their
being included in the initial programme.
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Table II. Costs of different drug regimens (2001)
Cost per 
Regimen month (R)
First-step drugs (ddI, d4T, efavirenz or nevirapine) 700
Alternative first-step drugs (replace ddI with 3TC) 900
Second-step drugs (AZT, 3TC, efavirenz or 1 400
nevirapine or indinavir)
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Results of implementing the staff HIV
programme
The programme has been in place since November 2001. Since
then there has been a large amount of interest in the programme
from hospital staff as gauged by the number being tested for
HIV, having CD4 counts, going onto TB prophylaxis and being
placed on ARV therapy. For the 3-year period before that, viz.
January 1999  - December 2001, few staff members were
counselled and tested for HIV in the staff clinic (7 in 1999, 6 in
2000 and 11 in 2001). In late 2001, 2 had CD4 counts done and
were started on ARV therapy. One staff member paid for her
own treatment before the programme started, but died 2
months later of pulmonary Kaposi’s sarcoma. The other was
the first member to go onto the programme and responded
well to the treatment.
For the period January - December 2002, the first full
calendar year of the programme, 38 staff were counselled and
tested, a more than three-fold increase on the pattern of the
previous 3 years. As a result of this testing and others coming
forward, 21 HIV-positive staff had CD4 counts done. Eight of
these were given TB prophylaxis. By the end of 2002, 4 staff
members were on ARVs (3 of whom were also on TB
treatment) and all were doing well. In total 22 staff members
were on the programme (Fig. 1).
By August 2003, 27 staff members were on the programme,
and another 8 who had been on the programme had left the
hospital. Ten staff members were on ARV therapy, 4 of whom
were also on TB therapy. One pupil nurse who was on ARVs
had stopped treatment as she had finished her training and
had not yet found work. Another pupil nurse who was on
ARVs and TB treatment for 12 months stopped treatment after
developing treatment failure. She could not afford ‘second-
step’ drugs.
There have been many positive reactions to the programme.
Many of the staff HIV counsellors provide ongoing support to
their HIV-positive colleagues. An HIV-positive pupil nurse has
spoken about her status with many of her colleagues and has
encouraged them to go for testing. A professional nurse, who
was nursed by her colleagues when very ill, was initially very
frightened of being identified as HIV-positive. She has not told
many of her colleagues her status, but she does tell them she
went to the staff clinic to ‘find out what was wrong’ and got
‘the right treatment’. However there are still staff members in
fear and denial. During the year 2002, 2 staff members known
to the staff doctor died of suspected AIDS. Both had refused
HIV testing.
Costs for the 12-month period January
2002 - December 2002
The cost to McCord for the first calendar year of providing
ARVs and monitoring bloods (i.e. CD4 and viral loads) was
approximately R40 210 (Table III). Only 1 staff member was on
treatment for the whole year. The other 3 started at various
times through the year. Three were on ‘first-step’ drugs and 1
was on ‘alternative first-step’ drugs. In the first year no staff
members were on ‘second-step’ drugs and therefore all the
costs were borne by the hospital. These figures are for ARVs
and HIV bloods only. Should their prices decrease, substantial
savings would result.
Conclusions
We believe that this programme represents the first formal
attempt by a South African hospital to offer HIV treatment and
care to its staff. The development of the programme was
motivated by the increasing number of staff members who
were sick and dying of AIDS. We believe that such a
programme can serve as a model for other institutions that
may wish to embark on HIV testing and treatment for their
staff.13
The programme was developed with the following essential
elements. Firstly, the programme was discussed with all groups
within the hospital including management, unions, the staff
HIV counsellors, and in small groups, the staff themselves.
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Fig. 1. Results of the McCord Hospital HIV staff programme.
Table III. Costs of antiretrovirals and HIV bloods for first 12
months of the programme
Cost (R)
Antiretrovirals for 4 staff members who started 
treatment at various times through the year 28 800
CD4 and viral loads for 4 staff members 
on antiretrovirals 8 800
CD4 count only on annual check-ups on 18 staff 2 610
Total 40 210
SAMJ FORUM
Secondly, the service was located within the staff clinic, a
family practice within the hospital. The service is therefore
comprehensive, managing minor ailments, chronic illnesses, TB
and HIV. It is also confidential in that the staff do not have to
fear they will be seen going to an HIV clinic and in that all the
counselling, testing, prescribing and follow-up is done by the
one staff doctor. Thirdly, the staff doctor (KU) has had access to
expert advice and support from the TB services at Durban
Chest Clinic and from an experienced HIV physician (GF). The
major clinical challenges have been from the rapid and
complicated presentations of TB in many of these severely
immunocompromised patients.
Some difficulties were encountered with the programme.
Firstly, there were side-effects with ‘first-step’ drugs. Peripheral
neuropathy has been the major problem and was experienced
by all 3 staff members on ddl and d4T regimens in the first
year. This was especially so for the 2 who were also on
isoniazid-containing TB regimens. All 3 managed to cope with
the side-effects with pyridoxine supplementation and the
symptoms remitted spontaneously or on completion of TB
treatment. The decreasing costs of ARV drugs will make it
possible to offer regimens of comparable efficacy and reduced
side-effects and toxicity.
Secondly, because of confidentiality concerns, all of the
adherence counselling was done by the staff doctor. However, 2
of the staff were poorly adherent, not fully understanding the
importance of or being able to maintain 100% adherence. This
was compounded in these 2 staff members by the high pill
burden. They were both on TB treatment and 1 was also taking
fluconazole for secondary prophylaxis of cryptococcal
meningitis. Poor adherence probably contributed to treatment
failure in 1 of them.8 We are now using two extra strategies to
support adherence —  treatment diaries and identifying
treatment supporters from among family or friends.
Thirdly, the fact that the counselling, testing, prescribing
and follow-up is done by the one staff doctor has been both a
bonus and a problem. It has helped protect confidentiality but
has been labour-intensive for the doctor running a busy staff
clinic. The addition to the programme of a senior counsellor
acceptable to all staff would make a difference. However, this
person would have to have other responsibilities apart from
HIV counselling so that staff do not fear being identified as
being HIV-positive by going to this counsellor. Even so, staff
may still not be willing to discuss their HIV with a designated
staff HIV counsellor.
Despite these difficulties, our experience indicates that
offering HIV care and treatment to health care workers is
humane, feasible and cost-effective and represents an
important entry point for the use of ARV therapy in South
Africa.
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